Respiratory Distress SyndromeNCT06549283
Nasal Intermittent Positive Pressure Ventilation During Neonatal Intubation
A study testing Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation in people with Respiratory Distress Syndrome and Intubation; Difficult or Failed, run by Muğla Sıtkı Koçman University at 2 sites in Turkey (Türkiye).
Trial summary
The study aims to determine whether the use of nasal intermittent positive pressure ventilation (NIPPV) during neonatal endotracheal intubation increases the rate of successful intubation without physiological instability during all intubation attempts. Read more about this study
- Who is it for?
- Ages 1 day to 28 days
- Conditions the study is for
- Respiratory Distress Syndrome, Intubation; Difficult or Failed, Newborn Morbidity
- What is being tested?
- Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 146 participants
- Where
- 2 sitesTurkey (Türkiye)
- Study dates
- 1 May 2023to 15 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 28 days
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Infants of a gestational age of 22-41 weeks and undergoing oral endotracheal intubation in the neonatal intensive care within the first 28 days of life
Who cannot join
- The infants who required urgent intubation,
- Infants intubated in the delivery room or the operating room,
- Infants with a heart rate of <120/min prior to randomization,
- Infants with airway or lung anomalies,
- Infants with cyanotic congenital heart disease,
- Infants NIPPV treatment was contraindicated (congenital nasal anomaly, congenital diaphragmatic hernia, or abdominal wall defect)
Trial locations and contacts
2 sites in 1 country.
Turkey (Türkiye)2 sites
Akdeniz University School of Medicine, Department of Neonatology
Antalya, 07000
Mugla Training and Research Hospital, Department of Neonatology
Menteşe, Muğla, 48000
About this study
Official title: Nasal Intermittent Positive Pressure Ventilation (NIPPV) During Neonatal Endotracheal Intubation: A Randomized Controlled Trial
The study aims to determine whether the use of nasal intermittent positive pressure ventilation (NIPPV) during neonatal endotracheal intubation increases the rate of successful intubation without physiological instability during all intubation attempts.
The present study was designed as a prospective, multicenter, randomized, controlled study conducted with neonates undergoing endotracheal intubation. The infants were assigned randomly to either the NIPPV group or the standard care group.
Read the detailed description
The present study was designed as a prospective, multicenter, randomized, controlled trial. The study was conducted at two tertiary Neonatal Intensive Care Units (Mugla Training and Research Hospital, Mugla, Turkey; Akdeniz University School of Medicine, Antalya, Turkey) between May 2023 and May 2024. Written informed consent was obtained from the parents of each neonatal patient prior to enrollment in the study.
Participants:
Infants of a gestational age of 22-41 weeks and undergoing oral endotracheal intubation in the neonatal intensive care unit within the first 28 days of life were eligible for inclusion in the present study. The infants who required urgent intubation, those intubated in the delivery room or the operating room, infants with a heart rate of <120/min prior to randomization, those with airway or lung anomalies, the ones with cyanotic congenital heart disease, and the ones for whom nasal intermittent positive pressure ventilation (NIPPV) treatment was contraindicated (congenital nasal anomaly, congenital diaphragmatic hernia, or abdominal wall defect) were excluded from the study.
Randomization:
Each infant was randomly assigned to either the intervention group or the standard-care group. Sequential numbers were generated in the neonatal intensive care unit's computer with an allocation ratio of 1:1. The numbers were concealed in opaque, sequentially numbered, sealed envelopes. The physician on call opened sequentially numbered sealed opaque envelopes and randomized infants to respective groups before procedure.
Definitions:
An attempt was defined as an airway maneuver, which commenced with the insertion of the laryngoscope blade (conventional) into the mouth of the patient and ended with the removal of the blade. Successful airway management was defined as the placement of an endotracheal tube in the trachea, confirmed based on chest elevation, auscultation, second independent laryngoscopy, carbon dioxide detection, and/or chest radiography. First-attempt success was defined as successful intubation by the first practitioner on the first attempt. Multiple-attempt success was defined as the requirement of over two attempts (≥3) for successful intubation. The requirement for single, two, or multiple attempts for successful intubation was defined as all intubation attempts. Severe oxygen desaturation during intubation was defined as a decrease of ≥20% in oxygen saturation relative to the highest level of oxygen saturation recorded prior to the first attempt. Bradycardia was defined as a heart rate of <100 beats per minute. Physiological instability was defined as severe desaturation (a decrease of >20% in oxygen saturation relative to that immediately prior to pre-laryngoscopy) or bradycardia (a heart rate of <100 beats per minute) during the intubation attempts.
Interventions:
All neonates were monitored using a Philips monitor (IntelliVue MX450) that displayed the real-time peripheral oxygen saturation (SpO2) and heart rate prior to, during, and after the procedure. The patients were divided into two groups: the NIPPV group and the standard care group. In the NIPPV group, NIPPV was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). Appropriately-sized bi-nasal cannulae (Optiflow Junior, Fisher and Paykel, Auckland, New Zealand) were placed prior to laryngoscopy as interface for NIPPV implementation. NIPPV was implemented using Drager Babylog 8000 (Draeger Medicals Inc., Lubeck, Germany) or Leoni Plus (Löwenstein Medical, Bad Ems, Germany) mechanical ventilator. Non-synchronized NIPPV was implemented. NIPPV was initiated prior to intubation, with the peak inspiratory pressure set to 16-20 cmH2O (selected according to the infant's birth weight and chest wall expansion), positive-end expiratory pressure set to 6 cmH2O, breathing rate set to 40-50 breaths/min, inspiratory time set to 0.40-0.45 s, and flow rate set to 8-12 L/min. After the first successful intubation attempt, NIPPV was discontinued. Prior to laryngoscopy, the fraction of inspired oxygen (FiO2) was adjusted to maintain SpO2 above 90%. In the standard care group, the intubation attempt proceeded without NIPPV or supplemental oxygen. In the event of failure in the intubation attempt, SpO2 was increased above 90%, and the heart rate was increased above 120/min by applying positive pressure ventilation using a face mask prior to initiating the next intubation procedure. The size of the intubation tube was determined based on the baby's body weight [12]. Stylet was not used during intubation. Endotracheal intubations were performed either by pediatric research assistants or a neonatologist. A conventional laryngoscope with a straight blade was used for the intubation. Video laryngoscope was not used. Data accuracy was ensured by videotaping the monitor-displayed heart rate and SpO2 during the intubation procedure. After intubation, an independent assessor who was not part of the intubation team reviewed all recorded videos to document the obtained data on a case report form.
Data collection and management:
Data for demographic and clinical characteristics were collected for all patients. A pre-assigned staff member who was not a part of the intubation team noted the vital signs, adverse outcomes, and complications during and after the procedure and also collected blood gas one hour after the intubation for each patient.
Trial outcomes:
The primary outcome was successful intubation without physiological instability during all intubation attempts in the neonate. The secondary outcome was the lowest SpO2 level, lowest heart rate, bradycardia, severe desaturation, duration of severe desaturation, successful intubation on the first attempt without physiological instability, and time to successful intubation.
Sample size:
Hodgson et al. reported that the rate of successful intubation on the first attempt without physiological instability was 31% in newborns who did not receive additional respiratory support during intubation. In the present study, it was hypothesized that the success rate of intubation on the first attempt without physiological instability would increase from 31% to 54% upon the implementation of NIPPV during intubation. The sample size was calculated using the "G*Power 3.1.9.4" program with a type I error of 5% level and a power of 80%. Accordingly, it was concluded that 75 intubation episodes were required for each group, and 150 intubation episodes were required in total.
Statistical analysis:
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 25; Armonk, NY: IBM Corp.). The Kolmogorov-Smirnov and Shapiro-Wilk tests were conducted to determine the normal distribution of data. Student's t-test was conducted to compare the continuous parametric variables. The Mann-Whitney U-test was conducted to compare variables with non-normal distribution. Chi-squared or Fisher's exact test was conducted to analyze the categorical variables. Categorical variables were expressed as numbers (%). Normally distributed variables were expressed as mean ± standard deviation values. Non-parametric continuous variables were expressed as median values (interquartile range). The difference with p < 0.05 was considered statistically significant.
- Conditions
- Respiratory Distress Syndrome, Intubation; Difficult or Failed, Newborn Morbidity, Desaturation of Blood, Ventilator Lung; Newborn
- Being tested
- Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation
- Medical subject headings
- Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubationDevice
Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
| Study group | Role | What they receive |
|---|---|---|
| NIPPV group | Active comparator | Nasal intermittent positive pressure ventilation (NIPPV) was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). Appropriately-sized bi-nasal cannulae were placed prior to laryngoscopy as interface for NIPPV implementation. Non-synchronized NIPPV was implemented. NIPPV was initiated prior to intubation, with the peak inspiratory pressure set to 16-20 cmH2O (selected according to the infant's birth weight and chest wall expansion), positive-end expiratory pressure set to 6 cmH2O, breathing rate set to 40-50 breaths/min, inspiratory time set to 0.40-0.45 s, and flow rate set to 8-12 L/min. After the first successful intubation attempt, NIPPV was discontinued. Prior to laryngoscopy, the fraction of inspired oxygen (FiO2) was adjusted to maintain SpO2 above 90%. Receives: Device: Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation |
| Standard-care group | No intervention | The intubation attempt proceeded without NIPPV or supplemental oxygen. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Successful intubation without physiological instability during all intubation attempts
Successful intubation was defined as the placement of an endotracheal tube in the trachea, confirmed based on chest elevation, auscultation, second independent laryngoscopy, carbon dioxide detection, and/or chest radiography.
Physiological instability was defined as severe desaturation (a decrease of >20% in oxygen saturation relative to that immediately prior to pre-laryngoscopy) or bradycardia (a heart rate of <100 beats per minute) during the intubation attempts.
All intubation attempts was defined as the requirement for single, two, or multiple attempts for successful intubation.
Measured: One year
Secondary outcomes (7)
Lowest SpO2 level
Lowest peripheral oxygen saturation level during intubation
Measured: One year
Lowest heart rate
Lowest heart rate during intubation
Measured: One year
Bradycardia
Bradycardia was defined as a heart rate of <100 beats per minute
Measured: One year
Severe desaturation
Severe desaturation was defined as a decrease of ≥20% in oxygen saturation relative to the highest level of oxygen saturation recorded prior to the first attempt
Measured: One year
Successful intubation on the first attempt without physiological instability
Successful intubation was defined as the placement of an endotracheal tube in the trachea, confirmed based on chest elevation, auscultation, second independent laryngoscopy, carbon dioxide detection, and/or chest radiography.
Physiological instability was defined as severe desaturation (a decrease of >20% in oxygen saturation relative to that immediately prior to pre-laryngoscopy) or bradycardia (a heart rate of <100 beats per minute) during the intubation attempts.
Measured: One year
Time to successful intubation
Time until successful intubation is achieved. Successful intubation was defined as the placement of an endotracheal tube in the trachea, confirmed based on chest elevation, auscultation, second independent laryngoscopy, carbon dioxide detection, and/or chest radiography.
Measured: One year
Duration of severe desaturation
Duration of severe desaturation during intubation attempts. Severe desaturation was defined as a decrease of ≥20% in oxygen saturation relative to the highest level of oxygen saturation recorded prior to the first attempt
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2024
- Study start1 May 2023
- Primary completion1 May 2024
- Study completion15 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory Distress SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The patients were divided into two groups: the NIPPV group and the standard care group. In the NIPPV group, NIPPV was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). In the standard care group, the intubation attempt proceeded without NIPPV or supplemental oxygen.
- Masking
- None (open label)
- Enrolment
- 146 participants (actual)
Sponsor and investigators
- Lead sponsor
- Muğla Sıtkı Koçman University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ozkan Ilhan, Muğla Sıtkı Koçman University
- Investigators
- Ozkan Ilhan, Assoc Prof, Principal investigator, Muğla Sıtkı Koçman University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06549283
- Sponsor's protocol ID
- MSKU-NICU-OI-01
- Status last verified
- Aug 2024
- First submitted
- 8 Aug 2024
- Last updated
- 12 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Our data is available upon request, and we are committed to providing access to interested researchers for the purpose of scientific inquiry.
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nasal Intermittent Positive Pressure Ventilation (NIPPV) During Neonatal Endotracheal Intubation: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06549283
- Acronym / sponsor ID
- MSKU-NICU-OI-01
- Conditions
- Respiratory Distress Syndrome, Intubation; Difficult or Failed, Newborn Morbidity, Desaturation of Blood, Ventilator Lung; Newborn
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 146 participants (actual)
- Lead sponsor
- Muğla Sıtkı Koçman UniversityUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 1 May 2024 (actual)
- Study completion
- 15 Jul 2024 (actual)
- First posted
- 12 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to determine whether the use of nasal intermittent positive pressure ventilation (NIPPV) during neonatal endotracheal intubation increases the rate of successful intubation without physiological instability during all intubation attempts.
The present study was designed as a prospective, multicenter, randomized, controlled study conducted with neonates undergoing endotracheal intubation. The infants were assigned randomly to either the NIPPV group or the standard care group.
Detailed description
The present study was designed as a prospective, multicenter, randomized, controlled trial. The study was conducted at two tertiary Neonatal Intensive Care Units (Mugla Training and Research Hospital, Mugla, Turkey; Akdeniz University School of Medicine, Antalya, Turkey) between May 2023 and May 2024. Written informed consent was obtained from the parents of each neonatal patient prior to enrollment in the study.
Participants:
Infants of a gestational age of 22-41 weeks and undergoing oral endotracheal intubation in the neonatal intensive care unit within the first 28 days of life were eligible for inclusion in the present study. The infants who required urgent intubation, those intubated in the delivery room or the operating room, infants with a heart rate of <120/min prior to randomization, those with airway or lung anomalies, the ones with cyanotic congenital heart disease, and the ones for whom nasal intermittent positive pressure ventilation (NIPPV) treatment was contraindicated (congenital nasal anomaly, congenital diaphragmatic hernia, or abdominal wall defect) were excluded from the study.
Randomization:
Each infant was randomly assigned to either the intervention group or the standard-care group. Sequential numbers were generated in the neonatal intensive care unit's computer with an allocation ratio of 1:1. The numbers were concealed in opaque, sequentially numbered, sealed envelopes. The physician on call opened sequentially numbered sealed opaque envelopes and randomized infants to respective groups before procedure.
Definitions:
An attempt was defined as an airway maneuver, which commenced with the insertion of the laryngoscope blade (conventional) into the mouth of the patient and ended with the removal of the blade. Successful airway management was defined as the placement of an endotracheal tube in the trachea, confirmed based on chest elevation, auscultation, second independent laryngoscopy, carbon dioxide detection, and/or chest radiography. First-attempt success was defined as successful intubation by the first practitioner on the first attempt. Multiple-attempt success was defined as the requirement of over two attempts (≥3) for successful intubation. The requirement for single, two, or multiple attempts for successful intubation was defined as all intubation attempts. Severe oxygen desaturation during intubation was defined as a decrease of ≥20% in oxygen saturation relative to the highest level of oxygen saturation recorded prior to the first attempt. Bradycardia was defined as a heart rate of <100 beats per minute. Physiological instability was defined as severe desaturation (a decrease of >20% in oxygen saturation relative to that immediately prior to pre-laryngoscopy) or bradycardia (a heart rate of <100 beats per minute) during the intubation attempts.
Interventions:
All neonates were monitored using a Philips monitor (IntelliVue MX450) that displayed the real-time peripheral oxygen saturation (SpO2) and heart rate prior to, during, and after the procedure. The patients were divided into two groups: the NIPPV group and the standard care group. In the NIPPV group, NIPPV was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). Appropriately-sized bi-nasal cannulae (Optiflow Junior, Fisher and Paykel, Auckland, New Zealand) were placed prior to laryngoscopy as interface for NIPPV implementation. NIPPV was implemented using Drager Babylog 8000 (Draeger Medicals Inc., Lubeck, Germany) or Leoni Plus (Löwenstein Medical, Bad Ems, Germany) mechanical ventilator. Non-synchronized NIPPV was implemented. NIPPV was initiated prior to intubation, with the peak inspiratory pressure set to 16-20 cmH2O (selected according to the infant's birth weight and chest wall expansion), positive-end expiratory pressure set to 6 cmH2O, breathing rate set to 40-50 breaths/min, inspiratory time set to 0.40-0.45 s, and flow rate set to 8-12 L/min. After the first successful intubation attempt, NIPPV was discontinued. Prior to laryngoscopy, the fraction of inspired oxygen (FiO2) was adjusted to maintain SpO2 above 90%. In the standard care group, the intubation attempt proceeded without NIPPV or supplemental oxygen. In the event of failure in the intubation attempt, SpO2 was increased above 90%, and the heart rate was increased above 120/min by applying positive pressure ventilation using a face mask prior to initiating the next intubation procedure. The size of the intubation tube was determined based on the baby's body weight [12]. Stylet was not used during intubation. Endotracheal intubations were performed either by pediatric research assistants or a neonatologist. A conventional laryngoscope with a straight blade was used for the intubation. Video laryngoscope was not used. Data accuracy was ensured by videotaping the monitor-displayed heart rate and SpO2 during the intubation procedure. After intubation, an independent assessor who was not part of the intubation team reviewed all recorded videos to document the obtained data on a case report form.
Data collection and management:
Data for demographic and clinical characteristics were collected for all patients. A pre-assigned staff member who was not a part of the intubation team noted the vital signs, adverse outcomes, and complications during and after the procedure and also collected blood gas one hour after the intubation for each patient.
Trial outcomes:
The primary outcome was successful intubation without physiological instability during all intubation attempts in the neonate. The secondary outcome was the lowest SpO2 level, lowest heart rate, bradycardia, severe desaturation, duration of severe desaturation, successful intubation on the first attempt without physiological instability, and time to successful intubation.
Sample size:
Hodgson et al. reported that the rate of successful intubation on the first attempt without physiological instability was 31% in newborns who did not receive additional respiratory support during intubation. In the present study, it was hypothesized that the success rate of intubation on the first attempt without physiological instability would increase from 31% to 54% upon the implementation of NIPPV during intubation. The sample size was calculated using the "G*Power 3.1.9.4" program with a type I error of 5% level and a power of 80%. Accordingly, it was concluded that 75 intubation episodes were required for each group, and 150 intubation episodes were required in total.
Statistical analysis:
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 25; Armonk, NY: IBM Corp.). The Kolmogorov-Smirnov and Shapiro-Wilk tests were conducted to determine the normal distribution of data. Student's t-test was conducted to compare the continuous parametric variables. The Mann-Whitney U-test was conducted to compare variables with non-normal distribution. Chi-squared or Fisher's exact test was conducted to analyze the categorical variables. Categorical variables were expressed as numbers (%). Normally distributed variables were expressed as mean ± standard deviation values. Non-parametric continuous variables were expressed as median values (interquartile range). The difference with p < 0.05 was considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The patients were divided into two groups: the NIPPV group and the standard care group. In the NIPPV group, NIPPV was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). In the standard care group, the intubation attempt proceeded without NIPPV or supplemental oxygen.
| Arm | Type | Receives |
|---|---|---|
| NIPPV group | Active comparator | Device: Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubationNasal intermittent positive pressure ventilation (NIPPV) was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). Appropriately-sized bi-nasal cannulae were placed prior to laryngoscopy as interface for NIPPV implementation. Non-synchronized NIPPV was implemented. NIPPV was initiated prior to intubation, with the peak inspiratory pressure set to 16-20 cmH2O (selected according to the infant's birth weight and chest wall expansion), positive-end expiratory pressure set to 6 cmH2O, breathing rate set to 40-50 breaths/min, inspiratory time set to 0.40-0.45 s, and flow rate set to 8-12 L/min. After the first successful intubation attempt, NIPPV was discontinued. Prior to laryngoscopy, the fraction of inspired oxygen (FiO2) was adjusted to maintain SpO2 above 90%. |
| Standard-care group | No intervention | –The intubation attempt proceeded without NIPPV or supplemental oxygen. |
Who may qualify
- Ages
- 1 day to 28 days
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Infants of a gestational age of 22-41 weeks and undergoing oral endotracheal intubation in the neonatal intensive care within the first 28 days of life
Key exclusion criteria (6 listed)
- The infants who required urgent intubation,
- Infants intubated in the delivery room or the operating room,
- Infants with a heart rate of <120/min prior to randomization,
- Infants with airway or lung anomalies,
- Infants with cyanotic congenital heart disease,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubationResearchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation. | Device | NIPPV group |
Primary outcome
Successful intubation without physiological instability during all intubation attempts
Time frame: One year
Successful intubation was defined as the placement of an endotracheal tube in the trachea, confirmed based on chest elevation, auscultation, second independent laryngoscopy, carbon dioxide detection, and/or chest radiography. Physiological instability was defined as severe desaturation (a decrease of >20% in oxygen saturation relative to that immediately prior to pre-laryngoscopy) or bradycardia (a heart rate of <100 beats per minute) during the intubation attempts. All intubation attempts was defined as the requirement for single, two, or multiple attempts for successful intubation.
7 secondary outcomes
Lowest SpO2 level
Time frame: One year
Lowest heart rate
Time frame: One year
Bradycardia
Time frame: One year
Severe desaturation
Time frame: One year
Successful intubation on the first attempt without physiological instability
Time frame: One year
Time to successful intubation
Time frame: One year
Duration of severe desaturation
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2024.
- Individual participant dataSharing planned: No. Our data is available upon request, and we are committed to providing access to interested researchers for the purpose of scientific inquiry.
Related trials for Respiratory Distress Syndrome
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
RecruitingObservational study
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ARDS
Recruiting
Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants
Surfactant, Respiratory Distress Syndrome (Neonatal)
Recruiting
REspiratory MEchanics for Delivering Individualised Exogenous Surfactant
Respiratory Distress Syndrome in Premature Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ozkan Ilhan, Assoc Prof principal investigator
Muğla Sıtkı Koçman University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation in people with Respiratory Distress Syndrome and Intubation; Difficult or Failed, run by Muğla Sıtkı Koçman University at 2 sites in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Successful intubation without physiological instability during all intubation attempts (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2024.